Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tissue Repair Ltd ( (AU:TRP) ) has issued an update.
Tissue Repair Ltd has made significant progress in the March 2025 quarter, particularly with its TR987® drug, which is in Phase 3 trials for chronic wounds. Despite regulatory challenges in the US wound care market, the company is advancing its trials and expects to increase patient enrollment. Additionally, Tissue Repair is working on expanding the manufacturing capabilities for its TR Pro+® product, which saw record sales in March, and is pursuing distribution arrangements to enhance its market reach. Financially, the company reported a cash position of $12.6 million as of March 31, 2025, with ongoing investments in clinical trials and product development.
More about Tissue Repair Ltd
Tissue Repair Ltd is a biotechnology company focused on developing innovative treatments for chronic wounds and aesthetic medical procedures. Their primary products include TR987®, a drug in Phase 3 trials for venous leg ulcers and diabetic foot ulcers, and TR Pro+®, which targets both aesthetic and medical markets.
YTD Price Performance: -22.50%
Average Trading Volume: 50,326
Technical Sentiment Signal: Buy
See more data about TRP stock on TipRanks’ Stock Analysis page.